DDX43: A Potential Drug Target for Cancer (G55510)

Target Name: DDX43

NCBI ID: G55510

DDX43

DDX43: A Potential Drug Target for Cancer

DDX43 (DEAD box protein HAGE) is a gene that encodes a protein known to play a critical role in the development and progression of various diseases, including cancer. The protein is a member of the HSP70 family, which is a well-known group of proteins involved in various cellular processes, including stress responses, cytoskeletal organization, and signaling pathways. HSP70 proteins have been implicated in the development of many diseases, including cancer, neurodegenerative diseases, and systemic inflammatory diseases.

The HSP70 gene has been widely studied, and many different isoforms have been identified. HSP70 is a protein that can exist in various forms, including monomeric, dimeric, and trimeric forms. HSP70 monomers are typically found in the cytoplasm, while HSP70 dimers and trimers are more prevalent in the nucleus. The HSP70 protein plays a critical role in the maintenance of cellular homeostasis, as well as in signaling pathways that regulate cell growth, differentiation, and stress responses.

DDX43 is a specific isoform of the HSP70 gene that has been shown to be involved in various cellular processes, including cell signaling, DNA repair, and stress responses. The protein is expressed in various tissues and cells of the body, including muscle, liver, kidney, and brain. It is also expressed in various cell types that are under stress, such as cancer cells.

The Role of DDX43 in Cancer

Studies have shown thatDDX43 is involved in various aspects of cancer development, including the regulation of cell growth, apoptosis (programmed cell death), and angiogenesis (the formation of new blood vessels). In cancer cells, the levels of DDX43 are often increased, and the protein is involved in the maintenance of cellular homeostasis, as well as in signaling pathways that promote cell growth and survival.

One of the key functions of DDX43 is its role in cell signaling. The protein is involved in the regulation of various signaling pathways, including the TGF-β pathway, which is involved in cell growth, differentiation, and stress responses. The TGF-β pathway is a well-established mechanism for promoting cancer growth, and it is thought to be involved in the development of many diseases, including cancer.

DDX43 is also involved in the regulation of apoptosis, which is a critical mechanism for cell death that is regulated by various signaling pathways. Apoptosis is a natural mechanism that helps cells eliminate damaged or dysfunctional proteins, as well as pathogens that have invaded the cell. However, in cancer cells, the regulation of apoptosis can be disrupted, leading to the maintenance of cellular life cycle and the formation of tumors.

DDX43 is also involved in the regulation of angiogenesis, the formation of new blood vessels that supply oxygen and nutrients to cancer cells. The regulation of angiogenesis is critical for the growth and survival of cancer cells, and it is thought to be a key factor in the development of many diseases, including cancer.

The Potential of DDX43 as a Drug Target

The potential of DDX43 as a drug target is high due to its involvement in various cellular processes that are involved in cancer development. The protein is involved in cell signaling, apoptosis, and angiogenesis, and it is thought to be involved in the regulation of these processes in cancer cells. This suggests thatDDX43 could be an effective drug target for cancer treatment.

One of the key advantages of DDX43 as a drug target is its relatively simple structure. The protein has only four known isoforms, which makes it relatively easy to identify and target. Additionally, the protein has a relatively short half-life, which means that it is cleared from the body relatively quickly. This could make it an effective drug target, as it would be eliminated from the body more quickly than other proteins.

Another advantage of DDX43 is its potential to target multiple diseases. The protein is involved in various cellular processes that are involved in the development and progression of many diseases, including cancer. This suggests thatDDX43 could be an effective drug target for a wide range of diseases.

In addition, the potential of DDX43 as a drug target is supported by several preclinical studies. For example, studies have shown that inhibiting the activity of

Protein Name: DEAD-box Helicase 43

The "DDX43 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DDX43 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets